Skip to main content
SpringerLink
Log in

Novel Targets of Current Analgesic Drug Development

  • Chapter
  • First Online:
Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care

  • 4687 Accesses

Abstract

The development of new pharmaceutical agents for the treatment of pain seems at first like an ideal target for pharmaceutical companies. There is an enormous unmet need with a vast potential market. For many years, opioids and NSAIDs have remained the mainstay treatments in chronic pain, and while the advent of antiepileptic drugs and antidepressant medications into the indication arena for chronic and neuropathic pain has been helpful, it is far from adequate to meet the demands for controlling both acute and chronic pain. Hence, the pursuit of new novel medications for pain seems a rational action, but further insight shows how difficult the task truly is, not to mention the financial risks of such innovation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Melnikova I. Pain market. Nat Rev Drug Discov. 2010;9:589–90.

    Article  CAS  PubMed  Google Scholar 

  2. Dworkin R, Turk D, Katz N, Rowbotham M, Peirce-Sandner S, Cerny I, Clingman C, Eloff B, Farrar J, Kamp C, McDermott M, Rappaport B, Sanhai W. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain. 2011;152:S107–15.

    Article  PubMed  Google Scholar 

  3. McQue K. Newron’s ralfinamide fails for Katie McQue neuropathic pain. SCRIP World Pharmaceutical News. 7 May 2010. http://s3.amazonaws.com/cuttings/cuttingpdfs/9547/217fd9e47def65479dc4933329b5eb24.pdf.

  4. Schmidt W. 6th annual pain therapeutics summit. Oct 2013. www.painresearchforum.org/news/22419-filling-pain-drug-pipeline.

  5. ClinicalTrials.gov Identifier: NCT01693692, Sponsor Theravance, first received Sept 20, 2012. http://www.clinicaltrials.gov/ct2/show/NCT01693692.

  6. PRNewsire. KemPharm, Inc. Receives notice of allowance for novel pain drug candidate, KP201. 3 April 2013. http://www.prnewswire.com/news-releases-test/kempharm-inc-receives-notice-of-allowance-for-novel-pain-drug-candidate-kp201-201233571.html.

  7. Campbell CM, Kipnes MS, Stouch BC, Brady KL, Kelly M, Schmidt WK, Petersen KL, Rowbotham MC, Campbell JN. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815–23. doi:10.1016/j.pain.2012.04.014. Epub 2012 Jun 8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P, Egger M, Trelle S, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. doi:10.1136/bmj.c7086.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Talkington M. FDA advisory panel gives the green light to restart NGF antibody trials. Pain Research Forum. 13 March 2012. http://www.painresearchforum.org/news/14439-fda-gives-green-light-restart-ngf-antibody-trials.

  10. Fowler PD. Aspirin, paracetamol and non-steroidal anti-inflammatory drugs. A comparative review of side effects. Med Toxicol Adverse Drug Exp. 1987;2:338–66.

    Article  CAS  PubMed  Google Scholar 

  11. Kraft B. Is there any clinically relevant cannabinoid-induced analgesia? Pharmacology. 2012;89:237–46.

    Article  CAS  PubMed  Google Scholar 

  12. Li JX, Zhang Y. Emerging drug targets for pain treatment. Eur J Pharmacol. 2012;681:1–5.

    Article  CAS  PubMed  Google Scholar 

  13. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Ther. 1991;258:517–23.

    CAS  Google Scholar 

  14. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol. 1998;345:145–53.

    Article  CAS  PubMed  Google Scholar 

  15. Liu C, Walker JM. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. J Neurophysiol. 2006;96:2984–94.

    Article  CAS  PubMed  Google Scholar 

  16. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 1998;76:189–99.

    Article  CAS  PubMed  Google Scholar 

  17. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 2005;48:658–72.

    Article  CAS  PubMed  Google Scholar 

  18. Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology. 2008;109:101–10.

    Article  PubMed  Google Scholar 

  19. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169–72.

    Article  CAS  PubMed  Google Scholar 

  20. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006;104:1040–6.

    Article  CAS  PubMed  Google Scholar 

  21. Borgelt L, Franson K, Nussbaum A, Wang G. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33:195–209.

    Article  CAS  PubMed  Google Scholar 

  22. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Phil Trans R Soc B. 2012;367:3353–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160:467–79.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Groblewski T, et al. Pre-clinical pharmacological properties of novel peripherally-acting CB1-CB2 agonists. In: 20th annual symposium on the cannabinoids. Research Triangle Park: Int. Cannabinoid Research Society; 2010, p. 37.

    Google Scholar 

  25. Kalliomäki J, Annas P, Huizar K, Clarke C, Zettergren A, Karlsten R, Segerdahl M. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2013;40:212–8.

    Article  PubMed  Google Scholar 

  26. Kalliomaki J, Seqerdahl M, Webster L, Reimfelt A, Huizar K, Annas P, Karlsten R, Quiding H. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. Scan J Pain. 2013;4:17–22.

    Article  Google Scholar 

  27. Fanger CM, del Camino D, Moran MM. TRPA1 as an analgesic target. Open Drug Discov J. 2010;2:64–70.

    Article  CAS  Google Scholar 

  28. Radresa O, Dahllöf H, Nyman E, Nolting A, Alberta JS, Raboisson P. Roles of TRPA1 in pain pathophysiology and implications for the development of a new class of analgesic drugs. Open Pain J. 2013;6:S137–53.

    Article  Google Scholar 

  29. Trevisani M, Gatti R. TRPV1 antagonists as analgesic agents. Open Pain J. 2013;6:S108–18.

    Article  Google Scholar 

  30. Clapham DE. TRP channels as cellular sensors. Nature. 2003;426:517–24.

    Article  CAS  PubMed  Google Scholar 

  31. Montell C. Drosophila TRP channels. Pflugers Arch. 2005;451:19–28.

    Article  CAS  PubMed  Google Scholar 

  32. Lennertz RC, Kossyreva EA, Smith AK, Stucky CL. TRPA1 mediates mechanical sensitization in nociceptors during inflammation. PLoS One. 2012;7:e43597. doi:10.1371/journal.pone.0043597.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Nassini R, Pedretti P, Moretto N, Fusi C, Carnini C, et al. Transient receptor potential Ankyrin 1 channel localized to non-neuronal airway cells promotes non-neurogenic inflammation. PLoS One. 2012;7(8):e42454. doi:10.1371/journal.pone.0042454.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Kremeyer B, Lopera F, Cox JJ, Momin A, Rugiero F, Marsh S, Woods CG, Jones NG, Paterson KJ, Fricer FR, Villegas A, Acosta N, Pineda-Trujillo NG, Ramirez JD, Zea J, Burley MW, Bedoya G, Bennett DL, Wood JN, Ruiz-Linares A. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron. 2010;66(5):671–80.

    Article  CAS  PubMed  Google Scholar 

  35. Matta JA, Cornett PM, Miyares RL, Abe K, Sahibzada N, Ahern GP. General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci U S A. 2008;105(25):8784–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Kosugi M, Nakatsuka T, Fujita T, Kuroda Y, Kumamoto E. Activation of TRPA1 channel facilitates excitatory synaptic transmission in substantia gelatinosa neurons of the adult rat spinal cord. J Neurosci. 2007;27:4443–51.

    Article  CAS  PubMed  Google Scholar 

  37. Corey DP, Garcia-Anoveros J, Holt JR, Kwan KY, Lin SY, Vollrath MA, Amalfitano A, Cheung EL, Derfler BH, Duggan A, Geleoc GS, Gray PA, Hoffman MP, Rehm HL, Tamasauskas D, Zhang DS. TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells. Nature. 2004;432(7018):723–30.

    Article  CAS  PubMed  Google Scholar 

  38. A clinical trial to study the effects GRC 17536 in patients with painful diabetic peripheral neuropathy (painful extremities due to peripheral nerve damage in diabetic patients). Clinicaltrials.gov, identifier NCT01726413. Updated and verified as of December 2012 by Glenmark Pharmaceuticals Ltd, India. http://www.clinicaltrials.gov/ct2/show/NCT01726413?term=GRC-17536&rank=2.

  39. Business Wire. Cubist reports fourth quarter and full year 2012 financial results. www.thestreet.com. 23 Jan 2013.

  40. SBIR/STTR, Department of Health and Human Services. Analgesics targeting TRPA1 for treatment of chronic pain. Tracking number R43DA031516, solicitation year 2011. Principal investigator Herz, J of Algomedix, Inc. www.sbir.gov/sbirsearch/detail/368227.

  41. Nyman E, Franzén B, Nolting A, Klement G, Liu G, Nilsson M, Rosén A, Björk C, Weigelt D, Wollberg P, Karila P, Raboisson P. In vitro pharmacological characterization of a novel TRPA1 antagonist and proof of mechanism in a human dental pulp model. J Pain Res. 2013;6:59–70.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Borsook D, Edward A. Antineuropathic effects of the antibiotic derivative Spicamycin, KRN5500. Pain Med. 2004;5:104–8.

    Article  PubMed  Google Scholar 

  43. Kobierski L, Abdi S, DiLorenzo L, Feroz N, Borsook D. A single intravenous injection of KRN5500 (antibiotic spicamycin) produces long term decreases in multiple sensory hypersensitivities in neuropathic pain. Anesth Analg. 2003;97:174–82.

    Article  CAS  PubMed  Google Scholar 

  44. DiLorenzo L, Kobierski L, Moore KA, Borsook D. A water soluble synthetic Spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain. Neurosci Lett. 2002;330:37–40.

    Article  CAS  PubMed  Google Scholar 

  45. Abdi S, Vilassova N, Decosterd I, Feroz N, Borsook D. The effects of KRN5500, a spicamycin derivative, on neuropathic and nociceptive pain models in rats. Anesth Analg. 2000;91:955–99.

    Article  CAS  PubMed  Google Scholar 

  46. Weinstein S, Abernethy A, Spruill S, Pike I, Kelly AT, Jett LG. A Spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial. J Pain Symp Manag. 2012;43:679–91.

    Article  CAS  Google Scholar 

  47. Reuters Press Release. DARA BioSciences announces submission of KRN5500 to FDA for orphan designation. 29 Nov 2012.

    Google Scholar 

  48. Dolgin E. Panel backs pain drug studies with new safety checks. Nat Med. 2012;18:472.

    Article  CAS  PubMed  Google Scholar 

  49. McKelvey L, Shorten G, O’Keeffe G. Nerve growth factor-mediated regulation of pain signaling and proposed new intervention strategies in clinical pain management. J Neurochem. 2013;124:276–89.

    Article  CAS  PubMed  Google Scholar 

  50. Davies AM. Regulation of neuronal survival and death by extracellular signals during development. Embo J. 2003;22:2537–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Covaceuszach S, Capsoni S, Marinelli S, Pavone F, Ceci M, Ugolini G, Vignone D, Amato G, Paoletti F, Lamba D, Cattaneo A. In vitro receptor binding properties of a “painless” NGF mutein, linked to hereditary sensory autonomic neuropathy type V. Biochem Biophys Res Commun. 2010;391:824–9.

    Article  CAS  PubMed  Google Scholar 

  52. Gerber RK, Nie H, Arendt-Nielsen L, Curatolo M, Graven-Nielsen T. Local pain and spreading hyperalgesia induced by intramuscular injection of nerve growth factor are not reduced by local anesthesia of the muscle. Clin J Pain. 2011;2011(27):240–7.

    Article  Google Scholar 

  53. Svensson P, Castrillon E, Cairns BE. Nerve growth factor evoked masseter muscle sensitization and perturbation of jaw motor function in healthy women. J Orofac Pain. 2008;22:340–8.

    PubMed  Google Scholar 

  54. Rukwied R, Mayer A, Kluschina O, Obreja O, Schley M, Schmelz M. NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin. Pain. 2010;148:407–13.

    Article  CAS  PubMed  Google Scholar 

  55. Zhu Y, Colak T, Shenoy M, Liu L, Pai R, Li C, Mehta, Pasricha PJ. Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastroenterology. 2011;141:370–7.

    Article  CAS  PubMed  Google Scholar 

  56. Shelton DL, Sutherland J, Gripp J, Camerato T, Armanini MP, Phillips HS, Carroll K, Spencer SD, Levinson AD. Human trks: molecular cloning, tissue distribution, and expression of extracellular domain immunoadhesins. J Neurosci. 1955;15:477–91.

    Google Scholar 

  57. Wang H, Romano G, Frustaci ME, Sanga P, Ness S, Russell L, Fedgchin M, Kelly K, Thipphawong J. Analgesic efficacy of fulranumab in patients with painful diabetic peripheral neuropathy in a randomized, placebo-controlled, double-blind study. Neurology. 2013;80 (meeting abstract):S58.002.

    Google Scholar 

  58. Minde J, Toolanen G, Andersson T, Nennesmo I, Remahl IN, Svensson O, Solders G. Familial insensitivity to pain (HSAN V) and a mutation in the NGFB gene. A neurophysiological and pathological study. Muscle Nerve. 2004;30:752–60.

    Article  PubMed  Google Scholar 

  59. Carey K. Anti-nerve growth factor drugs exonerated. Nat Biotechnol. 2012;30:298.

    Article  CAS  Google Scholar 

  60. Loftus P. J&J delays plans for arthritis drug as FDA continues hold on testing. Wall Street J. 2013. http://online.wsj.com/article/BT-CO-20130207-714849.html.

  61. Clinicaltrials.gov. Study to evaluate safety/efficacy of a single pre-op dose of AYX1 injection to treat pain after knee replacement surgery. Identifier NCT01731730, verified March 2013.

    Google Scholar 

  62. Chen Z, Janes K, Chen C, Doyle T, Bryant L, Tosh DK, Jacobson KA, Salvemini D. Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J. 2012;26:1855–65. doi:10.1096/fj.11-201541. Epub 2012 Feb 17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Zou W, Song Z, Guo Q, Liu C, Zhang Z, Zhang Y. Intrathecal lentiviral-mediated RNA interference targeting PKCγ attenuates chronic constriction injury-induced neuropathic pain in rats. Hum Gene Ther. 2011;22:465–75. doi:10.1089/hum.2010.207. Epub 2011 Feb 26.

    Article  CAS  PubMed  Google Scholar 

  64. Rottapharm website. http://www.rotta.com/en/service/rd/areTerap/pain.html.

  65. Ossipov M. The perception and endogenous modulation of pain. Scientifica. 2012:561761, 25 p, Hindawi Publishing Corp. http://dx.doi.org/10.6064/2012/561761.

  66. GEN. Teva Enters Up-to-$376 M deal for xenon pain drug. 11 Dec 2012. http://www.genengnews.com/gen-news-highlights/teva-enters-up-to-376m-deal-for-xenon-pain-drug/81247756/.

  67. Goldberg YP, Price N, Namdari R, Cohen CJ, Lamers MH, Winters C, Price J, Young CE, Verschoof H, Sherrington R, Pimstone SN, Hayden MR. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012;153:80–5. doi:10.1016/j.pain.2011.09.008. Epub 2011 Oct 28.

    Article  CAS  PubMed  Google Scholar 

  68. Wall Street Journal. Teva gets orphan drug designation for XEN402. 2013 April 23.

    Google Scholar 

  69. Anand P, Shenoy R, Palmer J, Baines AJ, Lai RK, Robertson J, Bird N, Ostenfeld T, Chizh BA. Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain. 2011;15:1040–8.

    Article  CAS  PubMed  Google Scholar 

  70. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum. 2003;48:3308–19.

    Article  CAS  PubMed  Google Scholar 

  71. Cohen SP, Bogduk N, Dragovich A, Buckenmaier 3rd CC, Griffith S, Kurihara C, et al. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology. 2009;110:1116–26.

    Article  CAS  PubMed  Google Scholar 

  72. Sweitzer SM, Medicherla S, Almirez R, Dugar S, Chakravarty S, Shumilla JA, et al. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain. 2004;109:409–19.

    Article  CAS  PubMed  Google Scholar 

  73. Ji RR, Gereau 4th RW, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev. 2009;60:135–48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Obata K, Yamanaka H, Kobayashi K, Dai Y, Mizushima T, Katsura H, Fukuoka T, Tokunaga A, Noguchi K. Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci. 2004;24:10211–22.

    Article  CAS  PubMed  Google Scholar 

  75. Ostenfeld T, Krishen A, Lai RY, Bullman J, Baines AJ, Green J, Anand P, Kelly M. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study. Eur J Pain. 2013;17:844–57. doi:10.1002/j.1532-2149.2012.00256.x. Epub 2012 Dec 14.

    Article  CAS  PubMed  Google Scholar 

  76. GlaxoSmithKline study register, Study No: KIP113049, completed August 2010, http://download.gsk-clinicalstudyregister.com/files/42c7fc18-27c2-461e-9464-378441578185.

  77. Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, Aylward P, Tanguay JF, DeWinter RJ, Marber MS, Lerman A, Hasselblad V, Granger CB, Newby LK. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am Heart J. 2012;164:646–53.e3. doi:10.1016/j.ahj.2012.07.030. Epub 2012 Oct 16.

    Article  CAS  PubMed  Google Scholar 

  78. Tong SE, Daniels SE, Black P, Chang S, Protter A, Desjardins P. Novel p38α mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain. J Clin Pharmacol. 2012;52:717–28.

    Article  CAS  PubMed  Google Scholar 

  79. McCarthy T. EMA401 for treating neuropathic pain. Drug Discovery and Development. 2012 Dec 4. www.dddmag.com/articles/2012/12/ema401-treating-neuropathic-pain.

  80. Chakrabarty A, Liao Z, Smith PG. Angiotensin II receptor type 2 activation is required for cutaneous sensory hyperinnervation and hypersensitivity in a rat hind paw model of inflammatory pain. J Pain. 2013;14:1053–65. doi:10.1016/j.jpain.2013.04.002. Epub 2013 May 30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Guasti L, Gimoldi P, Diolisi A, Petrozzino MR, Gaudio G, Grandi AM, Rossi MG, Venco A. Treatment with enalapril modified the pain perception pattern in hypertensive patients. Hypertension. 1998;31:1146–50.

    Article  CAS  PubMed  Google Scholar 

  82. Wexler R, Greenlee W, Irvin J, Goldberg M, Prendergast K, Smith RD, Timmermans P. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem. 1996;39:625–56.

    Article  CAS  PubMed  Google Scholar 

  83. Press Release. PR Newswire, United Business Media. 27 Mar 2013. www.marketwatch.com/story/spinifex-receives-15m-in-rd-tax-incentive-for-research-activities-related-to-the-discovery-of-treatments-for-pain-2013-03-27.

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Jeffrey A. Katz MD & Honorio T. Benzon MD

Authors
  1. Jeffrey A. Katz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Honorio T. Benzon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey A. Katz MD .

Editor information

Editors and Affiliations

  1. Departments of Anesthesiology and Pharmacology, LSU Health Sciences Center, New Orleans, Louisiana, USA

    Alan David Kaye

  2. Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, Stockton, California, USA

    Adam M. Kaye

  3. Center for Perioperative Management and Medical Informatics, Brigham and Women’s Hospital, Boston, Massachusetts, USA

    Richard D. Urman

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Katz, J.A., Benzon, H.T. (2015). Novel Targets of Current Analgesic Drug Development. In: Kaye, A., Kaye, A., Urman, R. (eds) Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8948-1_55

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8948-1_55

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8947-4

  • Online ISBN: 978-1-4614-8948-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation